Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma × zipalertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lung Diseases 1 Carcinoma 1

Interventions

Cisplatin 19 Paclitaxel 15 Carboplatin 15 Gemcitabine 12 pembrolizumab 11 Fluorouracil 8 Specimen Handling 7 Radiotherapy 7 Nivolumab 6 Magnetic Resonance Spectroscopy 6 Docetaxel 6 cemiplimab 5 Sunitinib 5 Platinum 5 Oxaliplatin 5 Everolimus 5 Cyclophosphamide 5 Capecitabine 5 durvalumab 4 anlotinib 4 Radiotherapy, Intensity-Modulated 4 Pemetrexed 4 Drug Therapy 4 Cetuximab 4 1,2-diaminocyclohexaneplatinum II citrate 4 padeliporfin 3 epothilone B 3 atezolizumab 3 Panitumumab 3 Leucovorin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05967689 2026-03-10

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting

Carcinoma, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡